| scholarly article | Q13442814 |
| P50 | author | Paul W Huber | Q92119434 |
| P2093 | author name string | Olivia F Cox | |
| P2860 | cites work | SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation | Q22008651 |
| Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE | Q22010705 | ||
| Sumoylation pathway is required to maintain the basal breast cancer subtype | Q24297866 | ||
| Active site remodelling accompanies thioester bond formation in the SUMO E1 | Q24299970 | ||
| Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics | Q24304372 | ||
| GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5 | Q24307366 | ||
| The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA | Q24307375 | ||
| Sumoylation regulates lamin A function and is lost in lamin A mutants associated with familial cardiomyopathies | Q24310688 | ||
| Impaired endocytosis of the ion channel TRPM4 is associated with human progressive familial heart block type I | Q24312557 | ||
| Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity | Q24317318 | ||
| SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle | Q24318317 | ||
| Cbx4 governs HIF-1α to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity | Q24320715 | ||
| SUMO modification of Huntingtin and Huntington's disease pathology | Q24324137 | ||
| Regulation of cardiac specific nkx2.5 gene activity by small ubiquitin-like modifier | Q24329223 | ||
| SUMO-1 modification activates the transcriptional response of p53 | Q24529948 | ||
| Proper coronary vascular development and heart morphogenesis depend on interaction of GATA-4 with FOG cofactors | Q24602111 | ||
| SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer | Q26776081 | ||
| Mapping the SUMOylated landscape | Q26799547 | ||
| Regulation of epithelial-mesenchymal transition through SUMOylation of transcription factors | Q27010433 | ||
| Sumoylation regulates diverse biological processes | Q27865196 | ||
| The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition | Q27865256 | ||
| A new protease required for cell-cycle progression in yeast | Q27938681 | ||
| SUMO-mediated regulation of DNA damage repair and responses | Q28086764 | ||
| Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. | Q28117154 | ||
| A deficiency in SUMOylation activity disrupts multiple pathways leading to neural tube and heart defects in Xenopus embryos | Q64052248 | ||
| The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice | Q81571103 | ||
| Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation | Q81631304 | ||
| Planar cell polarity pathway genes and risk for spina bifida | Q82647827 | ||
| Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues | Q84439039 | ||
| SUMO-specific proteases and isopeptidases of the SENP family at a glance | Q88112691 | ||
| MicroRNA-mediated regulation of Ubc9 expression in cancer cells | Q39827346 | ||
| Synergistic activation of the human MnSOD promoter by DJ-1 and PGC-1alpha: regulation by SUMOylation and oxidation | Q39952558 | ||
| ZNF451 is a novel PML body- and SUMO-associated transcriptional coregulator | Q39957218 | ||
| A metastatic signature in entire lung adenocarcinomas irrespective of morphological heterogeneity | Q40231410 | ||
| Functional modulation of parkin through physical interaction with SUMO-1. | Q40235074 | ||
| Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein | Q40319470 | ||
| Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities | Q40405262 | ||
| SUMO-1 modification activated GATA4-dependent cardiogenic gene activity | Q40520891 | ||
| A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. | Q40601003 | ||
| Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels | Q41150904 | ||
| The role of SUMO-1 in cardiac oxidative stress and hypertrophy. | Q41961959 | ||
| SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure. | Q42255809 | ||
| PIASy-mediated sumoylation of Yin Yang 1 depends on their interaction but not the RING finger | Q42598546 | ||
| Autophagy is essential for cardiac morphogenesis during vertebrate development | Q42729290 | ||
| SUMO chains: polymeric signals | Q43194594 | ||
| Serum response factor is modulated by the SUMO-1 conjugation system | Q44466424 | ||
| Inflammatory factor-specific sumoylation regulates NF-κB signalling in glomerular cells from diabetic rats | Q45240028 | ||
| Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling | Q46122037 | ||
| Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif: a reversal of the bound orientation | Q46182845 | ||
| Small ubiquitin-like modifier-1 (SUMO-1) modification of thymidylate synthase and dihydrofolate reductase | Q46859912 | ||
| Extent of inhibition of α-synuclein aggregation in vitro by SUMOylation is conjugation site- and SUMO isoform-selective | Q46962603 | ||
| The Yin and Yang of YY1 in tumor growth and suppression. | Q48043669 | ||
| Luteolin Modulates SERCA2a Leading to Attenuation of Myocardial Ischemia/ Reperfusion Injury via Sumoylation at Lysine 585 in Mice | Q50110141 | ||
| SENP5, a SUMO isopeptidase, induces apoptosis and cardiomyopathy. | Q50641117 | ||
| Sumoylation and Its Contribution to Cancer. | Q51137572 | ||
| Manipulating PML SUMOylation via Silencing UBC9 and RNF4 Regulates Cardiac Fibrosis. | Q51159598 | ||
| SUMO targets the APC/C to regulate transition from metaphase to anaphase. | Q52352276 | ||
| Guiding Mitotic Progression by Crosstalk between Post-translational Modifications. | Q52372030 | ||
| Uncovering SUMOylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein. | Q53064370 | ||
| Luteolin inhibits apoptosis and improves cardiomyocyte contractile function through the PI3K/Akt pathway in simulated ischemia/reperfusion. | Q54558394 | ||
| CRISPR-Cas guides the future of genetic engineering | Q57166586 | ||
| Small-Molecule Inhibitors Targeting Protein SUMOylation as Novel Anticancer Compounds | Q57245024 | ||
| PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. | Q39373721 | ||
| S-adenosyl methionine regulates ubiquitin-conjugating enzyme 9 protein expression and sumoylation in murine liver and human cancers | Q39381663 | ||
| A comprehensive compilation of SUMO proteomics. | Q39583866 | ||
| UBC9-Mediated Sumoylation Favorably Impacts Cardiac Function in Compromised Hearts | Q39798030 | ||
| Sumoylation of Prox1 controls its ability to induce VEGFR3 expression and lymphatic phenotypes in endothelial cells | Q39808389 | ||
| Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3 | Q28145507 | ||
| Sumoylation of Mdm2 by protein inhibitor of activated STAT (PIAS) and RanBP2 enzymes | Q28210085 | ||
| SUMO: a history of modification | Q28243325 | ||
| mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer | Q28246258 | ||
| A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis | Q28255073 | ||
| FGF signalling and SUMO modification: new players in the aetiology of cleft lip and/or palate | Q28256022 | ||
| Concepts in sumoylation: a decade on | Q28257220 | ||
| Differential PIAS3 expression in human malignancy | Q28261248 | ||
| Complex SUMO-1 regulation of cardiac transcription factor Nkx2-5 | Q28477049 | ||
| Serum response factor is essential for mesoderm formation during mouse embryogenesis | Q28505560 | ||
| SUMO1-dependent modulation of SERCA2a in heart failure | Q28508610 | ||
| Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3 | Q28509725 | ||
| SUMO1 haploinsufficiency leads to cleft lip and palate | Q28586545 | ||
| Myogenic and morphogenetic defects in the heart tubes of murine embryos lacking the homeo box gene Nkx2-5 | Q28590994 | ||
| Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex | Q29617624 | ||
| SUMO and Chromatin Remodeling | Q30274768 | ||
| Transient early embryonic expression of Nkx2-5 mutations linked to congenital heart defects in human causes heart defects in Xenopus laevis | Q30480671 | ||
| Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure | Q30654383 | ||
| Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. | Q30831444 | ||
| SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas | Q33273549 | ||
| Ubc9 expression predicts chemoresistance in breast cancer | Q33579371 | ||
| SUMO-4: A novel functional candidate in the human placental protein SUMOylation machinery. | Q33699071 | ||
| The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome | Q33788682 | ||
| Identification of small ubiquitin-like modifier substrates with diverse functions using the Xenopus egg extract system | Q33850621 | ||
| SUMOylation of FOXM1B alters its transcriptional activity on regulation of MiR-200 family and JNK1 in MCF7 human breast cancer cells | Q33907729 | ||
| Expression of sumoylation deficient Nkx2.5 mutant in Nkx2.5 haploinsufficient mice leads to congenital heart defects | Q33934076 | ||
| SUMO4 and its role in type 1 diabetes pathogenesis | Q34008085 | ||
| Uncovering global SUMOylation signaling networks in a site-specific manner | Q34041994 | ||
| Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma | Q34293007 | ||
| Regulation of DNA damage responses by ubiquitin and SUMO. | Q34328184 | ||
| SUMO2 is essential while SUMO3 is dispensable for mouse embryonic development | Q34338850 | ||
| SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination | Q34581013 | ||
| Small ubiquitin-like modifier (SUMO)-mediated repression of the Xenopus Oocyte 5 S rRNA genes | Q34738008 | ||
| Substantially reduced expression of PIAS1 is associated with colon cancer development | Q34962991 | ||
| High-level SAE2 promotes malignant phenotype and predicts outcome in gastric cancer | Q34991201 | ||
| Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation | Q35085788 | ||
| PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencing | Q35107382 | ||
| Ubc9 regulates mitosis and cell survival during zebrafish development | Q35191018 | ||
| Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. | Q35378365 | ||
| Myocardin sumoylation transactivates cardiogenic genes in pluripotent 10T1/2 fibroblasts | Q35642137 | ||
| Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer | Q35789345 | ||
| Enhanced desumoylation in murine hearts by overexpressed SENP2 leads to congenital heart defects and cardiac dysfunction | Q35803643 | ||
| Luteolin Inhibits Ischemia/Reperfusion-Induced Myocardial Injury in Rats via Downregulation of microRNA-208b-3p | Q35866988 | ||
| Autophagy in cardiac myocyte homeostasis, aging, and pathology | Q36280867 | ||
| Drug discovery in the ubiquitin-proteasome system. | Q36525810 | ||
| SUMO: a multifaceted modifier of chromatin structure and function | Q36564384 | ||
| Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival | Q36717273 | ||
| Pathogenic mutations in Parkinson disease | Q36770206 | ||
| Essential and unexpected role of Yin Yang 1 to promote mesodermal cardiac differentiation | Q36777260 | ||
| Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy | Q36799136 | ||
| Sumo-1 function is dispensable in normal mouse development | Q36846094 | ||
| Serum response factor orchestrates nascent sarcomerogenesis and silences the biomineralization gene program in the heart | Q36976702 | ||
| SUMO wrestling with Ras. | Q36997854 | ||
| Sumoylation and regulation of cardiac gene expression | Q37097348 | ||
| PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells. | Q37214337 | ||
| Defective sumoylation pathway directs congenital heart disease | Q37273083 | ||
| Regulation of the p53 pathway by ubiquitin and related proteins | Q37769926 | ||
| Yin Yang 1: a multifaceted protein beyond a transcription factor | Q37843604 | ||
| Autophagy in protein and organelle turnover | Q37911124 | ||
| Emerging roles of the SUMO pathway in development | Q37926562 | ||
| Pharmacological treats for SUMO addicts | Q38713427 | ||
| The Ubiquitin-Like SUMO System and Heart Function: From Development to Disease. | Q38720402 | ||
| NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation | Q38952574 | ||
| Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation | Q39005647 | ||
| SUMO and the robustness of cancer | Q39108925 | ||
| PIASy mediates hypoxia-induced SIRT1 transcriptional repression and epithelial-to-mesenchymal transition in ovarian cancer cells | Q39127573 | ||
| SUMO1 modulates Aβ generation via BACE1 accumulation. | Q39279350 | ||
| PIASy-mediated Tip60 sumoylation regulates p53-induced autophagy. | Q39321762 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | protein sumoylation | Q3503705 |
| P304 | page(s) | 960-969 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Current Drug Targets | Q15724627 |
| P1476 | title | Developing Practical Therapeutic Strategies that Target Protein SUMOylation | |
| P478 | volume | 20 |
| Q64917488 | SUMOylating Two Distinct Sites on the A-type Potassium Channel, Kv4.2, Increases Surface Expression and Decreases Current Amplitude. | cites work | P2860 |
Search more.